Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech such as Traws Pharma means wading through pages of trial data, R&D footnotes, and milestone contingencies. Investors looking for pipeline updates, cash-runway signals, or dilution risk often get lost before reaching the relevant tables. That’s why Stock Titan gathers every Traws Pharma SEC filing in one place and converts jargon into plain language. From “Traws Pharma SEC filings explained simply” to pinpointing how Tivoxavir Marboxil trials affect revenue assumptions, our platform starts with the questions analysts actually ask.
The latest Traws Pharma annual report 10-K simplified by our AI highlights phase progression timelines, partnering agreements, and detailed R&D spend, while each Traws Pharma quarterly earnings report 10-Q filing is paired with instant variance analysis. Real-time alerts flag Traws Pharma Form 4 insider transactions in real-time so you can see executive stock movements minutes after they post. Need more depth? Our engine answers “understanding Traws Pharma SEC documents with AI” by offering side-by-side comparisons, sentiment heat maps, and drill-downs into non-cash charges.
Whether you want “Traws Pharma insider trading Form 4 transactions” before a data read-out, “Traws Pharma proxy statement executive compensation” to evaluate incentive alignment, or “Traws Pharma 8-K material events explained” after an unexpected clinical update, Stock Titan has you covered. Each document comes with concise, AI-powered summaries and hyperlinks to underlying tables, turning hours of manual review into minutes of actionable insight. Use our dashboard for Traws Pharma earnings report filing analysis, monitor Traws Pharma executive stock transactions Form 4 in real-time, and stay ahead of every disclosure that can move the share price.
Traws Pharma, Inc. (TRAW) reported an equity compensation grant to one of its directors, John Leaman. On 11/21/2025, he was granted a stock option to purchase 12,770 shares of Traws Pharma common stock at an exercise price of $2.31 per share. The option is held directly and expires on 11/21/2035.
The option vests over three years from the grant date, with 33% vesting on the first anniversary, 33% on the second anniversary, and the remaining 34% on the third anniversary. Following this grant, John Leaman beneficially owns 12,770 derivative securities in the form of these stock options.
Traws Pharma, Inc. reported Q3 results showing a net loss of $3.96 million as R&D and G&A totaled $2.31 million and $1.74 million, respectively. Cash and cash equivalents were $6.42 million at September 30, 2025, with total assets of $12.44 million. Stockholders’ equity improved to $4.55 million, aided by a sharp reduction in warrant liabilities.
For the nine months, the company recorded net income of $16.61 million, driven primarily by a $26.66 million non‑cash gain from the change in fair value and reclassification of warrant liabilities, and recognition of $2.79 million in revenue upon the termination of a legacy license. Operating cash outflow was $15.43 million year‑to‑date.
The company entered an ATM Agreement authorizing sales of up to $50 million in common stock and raised $3.27 million net by issuing 1,627,050 shares. It also acquired IP assets from Viriom for $2.35 million in cash, adding a patent now carried at $2.57 million. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern based on current cash projections.
Traws Pharma (TRAW) furnished an update on November 13, 2025 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and began using a new corporate presentation. Both materials were provided as Exhibits 99.1 and 99.2.
The materials under Item 7.01 are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced. The company also included standard forward-looking statements language.
Traws Pharma (TRAW) reported executive equity grants. On October 12, 2025, the board’s Compensation Committee approved stock options for five executives at an exercise price of $3.01 per share, each with a 10‑year term and one‑year cliff vesting (vesting in full on the first anniversary, subject to continued service). Grants include 64,839 options to the CEO, and 32,406 each to the CFO, Chief Science Officer (Virology), and Chief Medical Officer, plus 22,435 to the COO. Awards were made under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma (TRAW) reported an insider equity award. Chief Science Officer, Virology, Charles David Pauza acquired 32,406 stock options at an exercise price of $3.01 on 10/12/2025, as disclosed on Form 4.
The options vest 100% on 10/12/2026 and expire on 10/12/2035. Following the transaction, the reporting person beneficially owns 32,406 derivative securities directly. This reflects routine equity compensation.
Traws Pharma (TRAW) reported a director stock option grant on 10/12/2025. The filing shows a grant of 11,530 stock options with an exercise price of $3.01 per share. The options vest 100% on 10/12/2026 and expire on 10/12/2035.
Following the transaction, the reporting person held 11,530 derivative securities, with ownership listed as Direct. This was a routine equity award; no common shares were listed in the non-derivative table.
Traws Pharma, Inc. filed a Form 4 reporting a director stock option grant. On 10/12/2025, the reporting person received a stock option to purchase 11,530 shares of common stock at an exercise price of $3.01 per share.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following this grant, 11,530 derivative securities were beneficially owned on a direct basis. The filing lists no transactions in non-derivative common stock.
Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant. The award covers 11,530 options with an exercise price of $3.01 per share, granted on October 12, 2025.
The options vest 100% on the first anniversary of the grant date and become exercisable on October 12, 2026, with an expiration on October 12, 2035. Following the transaction, the reporting person held 11,530 derivative securities, reported as Direct (D) ownership.
Traws Pharma, Inc. (TRAW) filed a Form 4 disclosing a director stock option grant. On 10/12/2025, the reporting person acquired 11,530 stock options at a $3.01 exercise price. The options vest 100% on the first anniversary of the grant date and expire on 10/12/2035. Following the transaction, 11,530 derivative securities were beneficially owned on a direct basis.
Traws Pharma (TRAW) reported an insider equity grant. CEO and Director Iain Dukes received a stock option for 64,839 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following the grant, 64,839 derivative securities were beneficially owned, held directly. The filing reflects a routine equity compensation award.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
